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Abstract 
Background
A primary aim of Children’s Oncology Group (COG) study AREN0534 was to facilitate partial 
nephrectomy in 25% of children with bilaterally-predisposed unilateral tumors (WAGR, multifocal 
and overgrowth syndromes).  The purpose of this prospective study was to achieve an excellent 
EFS and OS, while preserving renal tissue through pre-operative chemotherapy, completing 
definitive surgery by 12 weeks from diagnosis, and modifying post-operative chemotherapy 
based on histologic response.  
Methods 
The treating institution identified if a predisposition syndrome existed.  Patients had central 
review of imaging studies through the biology and classification study AREN03B2 and then 
were eligible to enroll on AREN0534.   Patients were treated with induction chemotherapy 
determined by localized or metastatic disease on imaging (and histology if a biopsy had been 
undertaken). Surgery was based on radiographic response at 6 or 12 weeks. Further 
chemotherapy was determined by histology.  Favorable Histology Stage III or IV disease 
















This article is protected by copyright. All rights reserved
34 patients were evaluable. 13 were males and 21 were females with a mean age at diagnosis 
of 2.79 years (range: 0.49 – 8.78). Median follow-up was 4.49 years (range: 1.67-8.01).  
Underlying diagnosis included 9 with BWS, 9 with hemihypertrophy, 10 had multicentric tumors, 
2 had WAGR syndrome, 2 had a solitary kidney 1 had DDS, and 1 had Simpson-Golabi-Behmel 
syndrome. Four-year EFS and OS were 94.0% (95% CI: 85.2% - 100%) and 100%. Two 
patients relapsed (one tumor bed, one abdomen) and none had disease progression during 
induction. Using RECIST 1.1 criteria, radiographic response was CR (2), PR (21), SD (11) and 
PD (0). Post therapy histologic classification were 13 low-risk (including the 2 complete 
responders), 15 intermediate-risk, and 6 high-risk (one focal anaplasia and five blastemal 
subtype).     Prenephrectomy chemotherapy facilitated renal preservation in 22/34 patients 
(65%). 
Conclusions
A standardized approach of preoperative chemotherapy, surgical resection within 12 weeks and 
histology-based post-operative chemotherapy results in an excellent EFS/OS and preservation 
of renal parenchyma. 
 
Introduction 
The outcome for patients with unilateral favorable histology Wilms tumor (WT) is excellent with 
4-year event free survival (EFS) greater than 85%. (1-4)  A majority of these children never 
develop a metachronous tumor and the overall incidence of renal failure following treatment for 
most children with unilateral WT is low. However, there is a subpopulation of patients who are 
not only at risk for a unilateral WT but are predisposed to develop metachronous bilateral Wilms 
tumor.(5, 6) They are also  at higher risk of developing renal failure.(7) Examples of patients at 
risk for a second primary renal tumor include those with WT1 deletions and mutations, as seen 
in the Wilms tumor/Aniridia/Genitourinary anomalies/Range of developmental delays (WAGR), 
Denys-Drash and Frasier syndromes; overgrowth syndromes such as Beckwith-Wiedemann 
Syndrome (BWS), and syndromes associated with other chromosomal anomalies.(8) Many of 
these children will present with multi-centric disease due to an increased incidence of 
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predisposition.(9) Porteus reviewed the National Wilms Tumor Study Group experience with 53 
BWS patients; 44 had nephrogenic rests and 52/53 had favorable histology (FH) WT. Those 
with unilateral disease at presentation were reported to be at a significant risk (P = .02) for the 
development of metachronous contralateral lesions within 4 years (4.5%) compared to non-
BWS controls (0.5%).(10)  Breslow’s 1993 paper  defined the subpopulations that  are risk for 
either synchronous or metchronous bilateral  tumors including BWS. In  A more recent paper on 
BWS refines this risk based on the underlying genetic abnormality.(11)
The incidence of end stage renal disease (ESRD) is also much higher in these patients. Breslow 
reported a 38% risk of renal failure, occurring a median of 20 years after diagnosis of WT in 
these patients. The highest rate is in those with WT1 deletions.  In contrast, the 20-year 
cumulative incidence of ESRD for the non-syndromic group for survivors of sporadic unilateral 
WT was less than 0.6%. Possible etiologies for the ESRD include repeated chemo-, surgical- 
and radiotherapy resulting in loss of renal units, as well as the known impact of WT1 mutation 
on glomerular development and function. 
The increased risk of metachronous disease, coupled with the increased risk of ESRD, provided 
the impetus to maximize sparing of renal units in patients with unilateral WT and an underlying 
WT predisposition.   The Children’s Oncology Group (COG) study AREN0534 was the first 
clinical trial to prospectively enroll and uniformly treat these patients.  The aim was to facilitate 
partial nephrectomy in lieu of nephrectomy in 25% of children with unilateral tumors and bilateral 
predisposition syndromes, by using prenephrectomy induction chemotherapy. We report the 
results of this study.  
Methods 
Study 
The COG study AREN0534, “Treatment for Patients with Bilateral, Multi-centric, or Bilaterally-
Predisposed Unilateral Wilms Tumor” had three arms: one for treatment of patients with bilateral 
Wilms tumor , one for patients with unilateral tumors at risk for metachronous disease or multi-
centric tumors, and one for patients with diffuse hyperplastic perilobar nephroblastomatosis 
(DHPLN).(12) This report presents the results of children with unilateral tumors who are at risk 
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The National Cancer Institute Central Institutional Review Board (CIRB) reviewed and approved 
the study protocol.  Where regulatory agreements were in place, the CIRB approval was 
accepted by the local institutional review board. In collaborating sites without such an 
agreement, the local institutional research ethics board provided approval. All patients or their 
guardians provided written informed consent prior to enrollment. Enrollment was required within 
14 days of diagnosis or 7 days after starting therapy. To enroll on the unilateral arm of the study 
of AREN0534 patients were first enrolled on the COG biology and classification study 
AREN03B2 which provided central review of operative notes, diagnostic imaging and when 
available pathology review (10-12). Patients had to be < 30 years old at the time of initial 
diagnosis and have one of the following conditions unilateral WT and aniridia (WAGR), 
Beckwith-Wiedemann Syndrome, idiopathic hemihypertrophy, Simpson-Golabi-Behmel-
Syndrome, Denys-Drash Syndrome (DDS) or other genitourinary anomalies associated with 
bilateral Wilms tumor; multicentric WT (any age); or unilateral WT with contralateral nephrogenic 
rest(s) (any size) by imaging in a child under one year of age.(13) Patients with a solitary kidney 
could also enroll. Patients could enroll with or without a diagnostic biopsy but were excluded 
from this arm of the study if they had undergone a nephrectomy at diagnosis. If they had 
undergone a nephrectomy at diagnosis, they were treated on the standard unilateral protocol. 
Patients with a horseshoe kidney or inadequate cardiac or liver function were not eligible.  
Staging
Patients received both a local stage and an overall disease stage designation. The final local 
stage was based on the abdominal tumor burden, whereas the disease stage accounted for the 
presence of distant metastatic disease. All patients who had an initial biopsy (open, trucut or 
fine needle) were considered stage III. Open biopsies were strongly encouraged and fine needle 
biopsies because of the inherent difficulty in diagnosing rests from tumor were strongly 
discouraged The COG and Société Internationale d’Oncologie Pédiatrique (SIOP)  staging 
system have been well described and were used to classify patients treated with preoperative 
chemotherapy (14) Table 1.
Treatment
The overall strategy of the study was to administer prenephrectomy chemotherapy with the aim 
of shrinking the tumor to allow maximum preservation of renal parenchyma. Initial induction 
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imaging revealed local disease only.  Vincristine, dactinomycin and doxorubicin (regimen VAD) 
was used if no biopsy was performed and imaging revealed metastatic disease or if the tumor 
was biopsied and found to have favorable histology WT.  If anaplastic histology was found on 
biopsy regimen UH-1 was mandated by protocol (Table 2). Regimen UH-1 was revised mid-
study due to greater than expected toxicities observed on the companion AREN0321 study for 
high-risk renal tumors. Initial therapy included two 3-week cycles of chemotherapy (dosing and 
regimen in supplemental files 1). After two cycles (approximately six weeks) cross-sectional 
imaging was performed and a tumor response was assigned by central radiological review.   If 
partial nephrectomy was deemed feasible by the local institution, surgery was to be undertaken.  
If the tumors achieved a partial response (PR) but were not amenable to partial nephrectomy, 
chemotherapy was continued for another two cycles. If there was progressive disease after 2 
cycles or in some tumors stable disease a total nephrectomy was performed  If the tumors did 
not achieve a partial response (PR) after induction, a total nephrectomy was required by 
protocol.  After four cycles of chemotherapy (12 weeks), repeat cross sectional imaging was 
performed and either a partial or total nephrectomy was required. Table 3 (ABC) show the 
treatments based on response and histology from enrollment through to definitive surgery. 
Adverse events were reported using the Common Terminology Criteria for Adverse events 
version 5. 
Radiology Response Criteria.  Criteria used to assess tumor response included reduction in size 
and the ability to perform a nephron-sparing procedure. Response was based on the Response 
Evaluation Criteria in Solid Tumor (RECIST 1.1). (15) Target lesions were defined as lesions 
greater than 10 mm within the kidney. If multiple target lesions were present, the three largest of 
them were described. Overall response was not modified by extra renal target lesions nor non-
target disease. PR was defined as at least a 30% decrease in the sum of the diameters of target 
lesions (which equals to a 50% decrease in volume), taking as reference the baseline sum 
diameters. Progressive disease (PD) was defined as at least a 20% increase in the sum of the 
diameters of target lesions and stable disease (SD) as neither sufficient shrinkage to qualify for 
PR nor sufficient increase to qualify for PD.
Chemotherapy.  Adjuvant therapy was based on a final risk stratification taking into account 
SIOP tumor stage and histologic response after definitive renal surgery at either 2 or 4 cycles of 
chemotherapy.  (Tables 1, 2, 3)   The details of the chemotherapy regimens have been 
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Radiation Therapy.  Patients with favorable histology (FH) tumors who were stage III due to 
biopsy alone did not receive radiation therapy. For the other FH patients that were classified as 
abdominal stage III or focal anaplasia stage I-III or diffuse anaplasia stage I-II received flank 
radiotherapy with 10.8 Gy (19.8 Gy for ≥16 years old), .  Patients with stage III diffuse anaplastic 
histology received 19.8 Gy.   Patients required whole abdomen radiation due to preoperative 
tumor rupture, peritoneal metastases or a large intraoperative tumor spill affecting areas outside 
the tumor bed as determined by the surgeon. For those with FH received 10.5 Gy and those 
with diffuse anaplastic histology received 21 Gy.  All patients with stage IV disease with 
pulmonary metastasis received whole lung irradiation to a dose of 12 Gy (10.5 Gy for patients < 
12 months old), independent of radiological response.  
Statistical Considerations
The study was opened in July 2009, monitored by an independent data safety monitoring board, 
and was closed in June 2015 after reaching the accrual goal.  AREN0534 had three study arms 
with the statistical driver being the BILATERAL WILMS TUMOR arm. A target accrual of 234 
patients was required to enroll a minimum of 115 eligible patients with favorable histology 
bilateral Wilms tumor without high risk (blastemal subtype) features to meet the study’s 
statistical considerations. Interim efficacy monitoring was done at 25%, 50% and 75% of the 
expected information using an O’Brien-Fleming boundary (truncated at 3 standard 
deviations).(17) The unilateral predisposition arm accrued patients as long as the main bilateral 
Wilms tumorwas open.  Statistical methods used included Fisher exact test and Kaplan Meier 




Thirty-nine patients enrolled on the unilateral arm. Five patients were excluded for the following 
reasons:  one started treatment before signing the consent, one did not receive protocol 
therapy, and three had bilateral renal tumors at diagnosis. Table 4 describes the demographic 
and clinical characteristics of the 34 remaining patients: 13 were males and 21 were females 
with a mean age at diagnosis of 2.79 years (range: 0.49 – 8.78). Median follow-up was 4.49 
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10 had multicentric tumors, 2 had WAGR syndrome, 2 had a solitary kidney (one of these had a 
previous history of WT without a known predisposition syndrome and one was born with a single 
kidney also without a predisposition syndrome), 1 had DDS, and 1 had Simpson-Golabi-Behmel 
syndrome. 
Tumor Response and Surgical Resection
The tumor response to pre-nephrectomy chemotherapy among 34 patients with unilateral high 
risk tumors using the RECIST criteria for the least responsive tumors was CR (2), PR (21), SD 
(11) and PD (0).  Three patients were biopsied prior to starting therapy and the remaining 31 
were treated based on clinical and radiographic evidence. Thirty-two patients subsequently 
underwent surgery; 12 had a complete nephrectomy and 20 had a partial nephrectomy. There 
were 11 partial nephrectomies performed after two cycles of chemotherapy and 9 after four 
cycles of chemotherapy. Two tumors completely resolved on chemotherapy requiring no 
subsequent surgery. Prenephrectomy chemotherapy facilitated renal preservation in 22/34 
patients (65%).  Table 5 shows the surgical and clinical outcomes based on enrollment eligibility 
criteria.
Of the 32 with surgery, 15 had surgery after two cycles (week 6) of chemotherapy and 17 had 
surgery after 4 cycles (week 12).   The two patients who had complete resolution of their tumor 
were considered stage I disease and treated as such. Of the 32 who underwent a surgical 
procedure, post-surgical SIOP staging demonstrated 21 stage I, four stage II, six stage III (three 
due to positive margins) and one patient with local stage I was stage IV due to pulmonary 
metastasis. All but the child who was born with a solitary kidney had favorable histology. This 
child had focal anaplasia stage I. Using the SIOP post therapy histologic classification there 
were 13 low-risk (including the 2 complete responders), 15 intermediate-risk, and 6 high-risk 
(one focal anaplasia and five blastemal subtype). For the 10 multicentric tumors, multiple 
nodules were examined in 9 with 1/9 having discordant pathology. In this patient, one nodule 
was low risk and the other nodule was intermediate risk.  
There were 22 patients with a known predisposition syndrome where routine ultrasound 
screening would have been expected. Sixteen were stage I, three were stage II and three were 
stage III. In these cases, based on operative reports, 13 tumors were detected through routine 
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Four-year EFS and OS were 94.0% (95% CI: 85.2% - 100%) and 100%. (Figure 1) There were 
two events, one was a relapse in a child with BWS. This relapse occurred at 18 months off 
therapy and was in the original tumor bed. The initial treatment was with EE4A. The relapse 
histology was favorable histology WT.  The second event was a relapse in a child with 
multicentric disease. This child was given prenephrectomy chemotherapy, then underwent a 
partial nephrectomy with a positive margin and post-surgery had high-risk histology. The patient 
developed a new ipsilateral para-aortic lesion in the original radiation field at six months after 
completion of therapy. There was one grade IV toxicity (sinusoidal obstruction syndrome) on 
regimen DD4A that was self-limited.
Discussion 
The study aim for the multicentric or bilaterally- predisposed unilateral Wilms tumor treatment 
strata was to achieve partial nephrectomy in lieu of nephrectomy in a minimum of 25% of 
children by using prenephrectomy chemotherapy induction and a prescribed surgical timing 
approach.   We successfully exceeded that aim with renal preservation occurring in 65% of 
patients. In addition, we had outstanding outcomes with four-year EFS and OS estimates of 
94.9% (95%CI: 85.1% - 100%) and 100%.
Several interventions implemented on AREN0534 likely contributed to this improvement in 
outcome and renal unit preservation.  First, chemotherapy was tailored according to post-
chemotherapy SIOP-based histologic response.  Patients with diffuse anaplasia and blastemal 
subtype (high risk) received more intensive chemotherapy compared to previous studies.(18, 
19) A second intervention implemented on AREN0534 was to mandate definitive surgical 
resection after 2 or 4 cycles of chemotherapy, which was achieved in all patients. This is in 
contrast to historical practice where definitive surgery was often delayed months.(20)  A third 
factor that likely contributed to a better outcome is that we targeted a population of infants and 
children with an elevated risk for developing Wilms tumor due to their underlying genetic 
syndrome.  Hence, many were followed by screening ultrasound which may have resulted in 
patients being detected early with low stage tumors where both the outcomes and ability to 
perform renal preservation surgery would be predicted to be greater. Sixty-eight percent of the 
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consistent with previously published SIOP 2001 data in which 1397/2569 (55%) of patients were 
stage I after induction chemotherapy.(21) 
In this protocol we used induction prenephrectomy chemotherapy with the goal of nephron 
sparring surgery. Our justification was two-fold. First, these patients have a much higher risk of 
developing bilateral WILMS tumor.(6, 7, 22) Children with these high-risk syndromes also have 
a higher incidence of nephrogenic rests which are recognized as precursor lesions to WT.(9, 13) 
Our second justification is that syndromic Wilms tumor patients have a much higher risk of renal 
failure than non-syndromic unilateral WT patients. Breslow reported renal failure rate from the 
NWTS studies in these syndromic at close to 38% at 14 years after diagnosis of Wilms Tumor 
with the highest risk group being those with WT-1 related syndromes.(23-25) Also any 
syndrome associated with metachrounous WT carries an increased risk of ESRD due to the 
need for repeated surgical procedures.  
Although published after our study closed, the SIOP renal tumor group retrospective study done 
over 43 years with 34 BWS and hemi-hypertrophy patients supports our rationale for the 
study.(26)  Nine of 34 had renal preservation surgery and 25 had a complete nephrectomy. The 
risk of local relapse was similar in both groups. There were two deaths in that study. In a second 
retrospective single center study published in 2012, Romao et al reported on 13 children with 
predisposition syndromes; 8 were detected by screening and 6 underwent renal 
preservation.(27) They also reported excellent outcomes. 
A study from the National Wilms Tumor Study Group indicated that WT treatment was as 
effective in the setting of WAGR syndrome as in the general population of WT patients. (28) 
However, long-term survival was decreased in WAGR syndrome due to the high incidence of 
renal failure. More intensive therapy was recommended. This was concerning because WAGR 
patients have an intrinsic risk of renal failure developing in their teenage years whether or not 
they develop WT.  The  results of this study demonstrated excellent disease control  without 
intensifying chemotherapy for the WAGR patients.(29)  Both in this unilateral cohort and in the 
bilateral WILMS tumor cohort reported from AREN0534, the WAGR patients had outstanding 
outcomes without intensive therapy.(16) In this current report, the WAGR patients receive 
EE4A, a less toxic regimen as induction and after surgery. Furthermore, the 5 WAGR patients 
on AREN0534 who presented with bilateral WILMS tumor had VAD on induction were all found 
to be low risk at resection with stage I or II disease. They were subsequently treated with EE4A 
following resection. All of these children are alive without recurrences or renal dysfunction. This 
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hope that the renal preservation that the nephron-sparing approach allowed will decrease the 
long-term risk of ESRD. We plan to perform a long term follow up in this patient population 
All patients on this study had favorable histology except one who was born with a single kidney 
and no recognized underlying predisposition syndrome. Following neo-adjuvant treatment, five 
patients with favorable histology WT were blastemal subtype according to the SIOP criteria.  
Four were stage I treated with DD4A and one was stage III treated with Regimen I and all are 
alive.  Possibly with larger cohort of cases, anaplasia would have been encountered but we 
speculate that a different underlying biology may characterize these subpopulations. 
COG renal tumor studies generally require pathology prior to treatment and study enrollment. 
This study was an exception because patients could enroll based on imaging alone. The 
primary reasons to perform a biopsy at initial presentation are to avoid misdiagnosis of Wilms 
tumor and to detect anaplasia, as well as to identify biomarkers such as LOH 1p, 16q and 1q 
gain. The rate of misdiagnosis of Wilms tumor is low, between 1.6% to 5.5 % for unilateral renal 
tumors on SIOP studies.(30)  The rate is estimated to be even lower for the bilaterally 
predisposed unilateral tumor and in our study 32/34 started therapy without a biopsy and none 
were misdiagnosed.
The limitations of the study are inherent in its design. Although the EFS and OS reported here 
are outstanding and similar to non-syndromic unilateral WT, this was not a randomized 
controlled trial. Second, the study was not designed to determine the impact of this treatment 
strategy on late effects such as renal failure. Patients will be followed for 10 years to track the 
rate of renal failure during this extended time period. Third, while radiographic criteria were well 
defined for this study, we cannot be certain that some of the smaller lesions which resolved with 
neoadjuvant therapy may have been nephrogenic rests.  This might be true in the 2 patients in 
whom the lesions completely resolved. We did not use any of the biomarkers such as LOH at 1p 
and 16q or 1q gain that have been since validated in sporadic unilateral WT to direct therapy. 
We also noted that some patients underwent a total nephrectomy at week six based on the 
institutional choice rather than continuing with chemotherapy to see if a partial nephrectomy 
could have been performed Future work will examine the incidence and impact of these 
biomarkers in the bilateral and unilateral predisposed population.   Finally, although we could 
determine from the operative notes that 13/22 patients with a known predisposition syndrome 
underwent routine ultrasound screening, in the other nine it was undocumented, thus limiting 
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In summary, this is the largest prospective study of bilaterally-predisposed unilateral WT 
patients reported to date. This treatment approach including standardized two-drug preoperative 
chemotherapy, surgical resection within 12 weeks of diagnosis and histology-based post-
operative therapy showed excellent EFS and OS and preservation of renal parenchyma. 
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Low Completely Necrotic 
Favorable Histology  
Intermediate Nephroblastoma epithelial type 
Nephroblastoma stromal type 
Nephroblastoma mixed type 
 Nephroblastoma regressive type 
Nephroblastoma focal anaplasia type 
 
High Nephroblastoma blastemal type 
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Table 2 Chemotherapy Regimens for the AREN0534  
*for specific dosing details please see supplemental files   
Regimen Agents 
VAD Vincristine, dactinomycin, doxorubicin ( maximum 12 
weeks) 
EE-4A vincristine and dactinomycin (19 weeks) 
DD-4A Vincristine, dactinomycin, doxorubicin and radiation therapy 
(XRT) (25 weeks) 
 
Regimen I Vincristine, dactinomycin, doxorubicin, cyclophosphamide, 
and etoposide, as well as radiation therapy (XRT) (28 
weeks) 
 
UH-1/Revised UH-1 Vincristine, dactinomycin, doxorubicin, cyclophosphamide 
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Table 3 A, B and C  Treatment Regimens 
A. Treatment Regimens at induction  
UNILATERAL WILMS TUMOR WITH A PREDISPOSTION SYNDROME TO DEVELOP BWT, SOLITARY KIDNEY at 
enrollment 
 Initial imaging Initial Regimen 
Imaging only ( no histology) Localized disease by imaging no 
biopsy performed 
EE4A 
Imaging only ( no histology) Evidence of distant disease by 
imaging 
VAD 
Imaging and biopsy reveal 
favorable histology 
All patients VAD 
Imaging and biopsy reveal 
unfavorable histology 







































B. Treatment regimen after 2 cycles of chemotherapy  
UNILATERAL WILMS TUMOR WITH A PREDISPOSTION SYNDROME TO DEVELOP BWT, SOLITARY KIDNEY after 
2 cycles (week 6 imaging) 
CR by imaging  Localized disease by imaging no 
biopsy 
EE4A 
CR by imaging  Evidence of distant disease by 
imaging no biopsy 
EE4A 
Initial biopsy FH Wilms and CR by 
imaging after 6 weeks of 
chemotherapy 
 DD4A 
Initial biopsy revealed anaplastic 
Wilms tumor and CR by imaging 
after 6 weeks of chemotherapy 
Localized abdominal disease by 
imaging with or without distant 
metastases 
UH-1/Revised UH-1 
PARTIAL NEPHRECTOMY PERFORMED AT 6 WEEKS. FURTHER CHEMOTHERAPY IS BASED ON HISTOLOGY OF 
REMOVED TUMOR AND HIGHEST TUMOR STAGE. 
Histology Stage Regimen 
Blastemal subtype I DD-4A  
Blastemal subtype II Reg. I  
Blastemal subtype¹ III-IV  Reg. I (Section 4.5) +XRT 
Diffuse anaplastic Wilms tumor I DD-4A + XRT 
Focal anaplastic Wilms tumor I-III  DD-4A + XRT 
Focal anaplastic Wilms tumor IV  UH-1/RevisedUH-1  + XRT 
Diffuse anaplastic Wilms tumor II-IV  UH-1/Revised UH-1  + XRT 
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Intermediate risk histology I-II EE-4A (Section 4.2) 
Completely necrotic tumor¹ III-IV  DD-4A + XRT 
Intermediate risk histology¹ III-IV DD-4A + XRT 
INITIAL TREATMENT WAS BASED ON IMAGING ALONE WITH LESS THAN A PARTIAL RESPONSE. THESE 
PATIENTS REQUIRE TOTAL NEPHRECTOMY. 
Blastemal subtype I DD-4A  
Blastemal subtype II Reg. I  
Blastemal subtype¹ III-IV  Reg. I (Section 4.5) +XRT 
Diffuse anaplastic Wilms tumor I DD-4A + XRT 
Focal anaplastic Wilms tumor I-III  DD-4A + XRT 
Focal anaplastic Wilms tumor IV  RevisedUH-1  + XRT 
Diffuse anaplastic Wilms tumor II-IV  Revised UH-1  + XRT 
Completely necrotic tumor I-II EE-4A (Section 4.2) 
Intermediate risk histology I-II EE-4A (Section 4.2) 
Completely necrotic tumor¹ III-IV  DD-4A + XRT 
Intermediate risk histology¹ III-IV DD-4A + XRT 
PARTIAL RESPONSE BUT PARTIAL NEPHRECTOMY NOT FEASIBLE. NO SURGERY SHOULD BE PERFORMED. 
All I-IV 
Continue with chemo and 
reevaluate at week 12 
 
1Biopsy makes the patient Stage III for chemotherapy but patient will NOT require radiation therapy 
unless they meet other criteria for Stage III designation, such as positive lymph nodes. However , patients 
with anaplastic histology receive radiation therapy 
 
C. Treatment regimen after 4 cycles of chemotherapy  
UNILATERAL WILMS TUMOR WITH A PREDISPOSTION SYNDROME TO DEVELOP BWT, SOLITARY KIDNEY after 
4 cycles (week 12 imaging) 
IF DEFINITIVE SURGERY OCCURRED AT END OF WEEK 6 OR IF THERE WAS 
COMPLETE RADIOLOGICAL RESOLUTION AT END OF WEEK 6. 
Continue with regimen assigned 
at end of week 6  
AT END OF WEEK 6, THERAPY WAS TO CONTINUE WITH CHEMOTHERAPY 
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CR by imaging after 12 weeks of 
chemotherapy 
Localized disease by imaging no 
biopsy 
EE4A 
CR by imaging after 12 weeks of 
chemotherapy 
Evidence of distant disease by 
imaging or even if  biopsy 
performed 
EE4A 
Biopsy reveals FH Wilms and CR 
by imaging after12 weeks of 
chemotherapy 
 DD4A 
Biopsy reveals anaplastic Wilms 
and CR by imaging after12 weeks 
of chemotherapy 
Localized disease by imaging  UH-1/Revised UH 1 
Initial biopsy revelaed anaplstic  
WT and CR by imaging after 12 
weeks of chemotherapy 
Evidence of distant disease by 
imaging 
UH-1/Revised UH 1 
Nephrogenic Rest without WT NA EE4A 
AT END OF WEEK 6, THERAPY WAS TO CONTINUE WITH CHEMOTHERAPY BUT CR NOT ATTAINED. DEFINITIVE 
SURGERY REQUIRED EITHER PARTIAL NEPHRECTOMY IF FEASIBLE OR TOTAL NEPHRECTOMY IF NOT. 
Histology Stage Regimen 
Blastemal subtype I DD-4A  
Blastemal subtype II Reg. I  
Blastemal subtype¹ III-IV  Reg. I (Section 4.5) +XRT 
Diffuse anaplastic Wilms tumor I DD-4A + XRT 
Focal anaplastic Wilms tumor I-III  DD-4A + XRT 
Focal anaplastic Wilms tumor IV  RevisedUH-1  + XRT 
Diffuse anaplastic Wilms tumor II-IV after surgery no measureable 
disease  
Revised UH-1  + XRT 
Nephrogenic Rest without WT NA EE4A 
Completely necrotic tumor I-II EE-4A (Section 4.2) 
Intermediate risk histology I-II EE-4A (Section 4.2) 
Completely necrotic tumor¹ III-IV  DD-4A + XRT 
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1Biopsy makes the patient Stage III for chemotherapy but patient will NOT require radiation therapy 
unless they meet other criteria for Stage III designation, such as positive lymph nodes. However, patients 
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Table 4 Patient  
Demographics 
  
   
Characteristics Category Total N (%) 
Gender Female 21 (62%) 
 Male 13 (38%) 
Race American Indian or Alaskan 1 (3%) 
 Black or African American 4 (12%) 
 Unknown 3 (9%) 
 White 26 (76%) 
Ethnicity Hispanic or Latino 3 (9%) 
 Not Hispanic or Latino 30 (88%) 
 Unknown 1 (3%) 
Syndromes Beckwith-Wiedemann Syndrome (BWS) 9 (26%) 
 Denys-Drash Syndrome (DDS) 1 (3%) 
 Hemihypertrophy 9 (26%) 
 Simpson-Golabi-Behmel 1 (3%) 




Age (years) at diagnosis Median (range) 2.8 (0.5-8.8) 
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Table 5 Surgical and Clinical Outcomes by enrolment eligibility on AREN0534 
 
Eligibility Surgical Procedure  Events 
Beckwith Wiedemann 
N=9 
8 partial nephrectomies 
1 total nephrectomy 
One relapse/disease 
progression at 18 months 
Hemihypertrophy 
N=9 
2 complete resolution 
4 partial nephrectomies 





4 partial nephrectomies 
6 total nephrectomies 
 
One relapse in para-aortic 




1 partial nephrectomy 
1 total nephrectomy 
None 
Solitary kidney  
N=2 
2 partial nephrectomies None 
 
Denys Drash Syndrome 
N=1 
1 total nephrectomy None 
 Simpson-Golabi-Behmel 
N=1 
1 partial nephrectomy None 
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